Genmab and Incyte will test petosemtamab with a KRAS G12D inhibitor in metastatic colorectal cancer. Can dual pathway targeting overcome resistance?
Genmab's Rina-S cut progression risk by 71% and showed an overall survival benefit in Phase 3 ovarian cancer data. What remains before approval?
EU approval moves TECVAYLI plus daratumumab into earlier multiple myeloma treatment after Phase 3 data cut progression risk by 83.4%.
Genmab and AbbVie clarify that EPCORE DLBCL-1 missed its sole US overall survival endpoint despite a PFS benefit for epcoritamab.
TIVDAK enters China’s cervical cancer market with survival data. See why Zai Lab’s ADC approval matters beyond oncology headlines.
AbbVie’s Phase 3 epcoritamab data raise critical questions about survival endpoints and bispecific antibodies in relapsed lymphoma. Read the full analysis.
Genmab’s epcoritamab improved PFS in a Phase 3 DLBCL trial. Find out how this could reshape bispecific monotherapy in aggressive B-cell lymphoma care.
Genmab ends development of acasunlimab to focus on EPKINLY, petosemtamab, and Rina-S. Find out what this shift means for 4-1BB bispecifics today.